Spectroscopic analyser

• US 10,241,039 B2
• Filed: 12/13/2016
• Issued: 03/26/2019
• Est. Priority Date: 04/06/2011
• Status: Active Grant

• Current Assignee: Klein Medical Ltd.
• Original Assignee: Klein Medical Ltd.
• Inventors: Krouse, Donal Paul, Simpkin, Raymond Andrew, Smith, Bryan James
• Primary Examiner(s): Porta, David
• Assistant Examiner(s): Riddick, Blake
• Application Number:
  US15/377,914
• Publication Number:
  US 20170184494A1
• Time in Patent Office: 833 Days
• Field of Search: 25033907, 25033912, 25033908, 25033909, 356301
• CPC Class Codes: G01J 2003/1286 Polychromator in general
• CPC Class Codes: G01J 3/10 Arrangements of light sources specially adapted for spectrometry or colorimetry
• CPC Class Codes: G01J 3/28 Investigating the spectrum using colour filters G01J3/51
• CPC Class Codes: G01J 3/42 Absorption spectrometry; Double beam spectrometry; Flicker spectrometry; Reflection spectrometry beam switching arrangements G01J3/08
• CPC Class Codes: G01N 2021/3595 using FTIR
• CPC Class Codes: G01N 21/3577 for analysing liquids, e.g. polluted water
• CPC Class Codes: G01N 21/359 using near infrared light
• CPC Class Codes: G01N 21/84 Systems specially adapted for particular applications
• CPC Class Codes: G01N 2201/0612 Laser diodes
• CPC Class Codes: G01N 2201/0691 Modulated (not pulsed supply)

Abstract

An analyser 10 for identifying or verifying or otherwise characterising a liquid based drug sample 16 comprising: an electromagnetic radiation source 11 for emitting electromagnetic radiation 14a in at least one beam at a sample 16, the electromagnetic radiation comprising at least two different wavelengths, a sample detector 17 that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the sample, and a processor 18 for identifying or verifying the sample from the detected affected electromagnetic radiation, wherein each wavelength or at least two of the wavelengths is between substantially 1300 nm and 2000 nm, and each wavelength or at least two of the wavelengths is in the vicinity of the wavelength(s) of (or within a region spanning) a spectral characteristic in the liquid spectrum between substantially 1300 nm and 2000 nm.

Claims

1. An analyser for identifying or verifying a liquid drug for delivery to a patient to reduce risk of adverse drug events, the liquid drug comprising a drug in a base liquid, the liquid drug having a liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between substantially 1300 nm and 2000 nm, the analyser comprising:

an electromagnetic radiation source for emitting electromagnetic radiation at the liquid drug, the electromagnetic radiation comprising a plurality of different wavelengths between substantially 1300 nm and 2000 nm, wherein at least one of the wavelengths is at or in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum,

a liquid drug detector that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug and that provides output representing spectral information of the liquid drug spectrum at the wavelengths, and

a processor configured to identify or verify the liquid drug from the detector output by;

querying a database of reference liquid drugs and corresponding spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a reference drug in a base liquid, each reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising the at least one spectral characteristic feature between substantially 1300 nm and 2000 nm, there being sufficient spectral differences between the reference liquid drug spectrums at the least one spectral characteristic feature of the base liquid spectrum to provide discrimination between reference drugs, and

identifying or verifying the liquid drug using;

a) the detector output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs, wherein the discrimination between the reference drugs assists with the identifying or verifying the liquid drug.

2. An analyser according to claim 1 wherein the electromagnetic radiation comprises a plurality of electromagnetic radiation beams, each beam having a different wavelength.

3. An analyser according to claim 1 wherein the wavelengths span or capture a plurality of at least some of the spectral characteristic features in the liquid spectrum between 1300 nm and 2000 nm.

4. An analyser according to claim 1 wherein the liquid spectrum comprises two or more spectral characteristic features, and wherein:

each spectral characteristic feature falls in or spans a region of the liquid spectrum, and

each wavelength falls within one of the regions.

5. An analyser according to claim 1 wherein the spectral characteristic features comprise peaks, troughs, inflections, stable points or regions, plateaus, knees and/or slopes of the liquid spectrum.

6. An analyser according to claim 1 wherein the source is a plurality of lasers in a single package, each laser configured to emit an electromagnetic radiation beam at a fixed or tuneable wavelength.

7. An analyser according to claim 1 wherein the detector and/or source are temperature compensated to provide temperature stability, using thermistors and peltier devices in a closed loop system.

8. An analyser according to claim 1 wherein the processor, as part of identifying or verifying the liquid drug from the output from the detector:

turns off the source and measures the output of the detector, resulting in a dark current component, and

removes the dark current component from the output representing the detected affected electromagnetic radiation.

9. An analyser according to claim 1 wherein the source is further operated to emit electromagnetic radiation at the detector unaffected by the liquid drug, and the processor, as part of identifying or verifying the liquid drug from the output from the detector, measures output of the detector resulting from the emitted electromagnetic radiation unaffected by the liquid drug.

10. A method for identifying or verifying a liquid drug for delivery to a patient to reduce risk of adverse drug events, the liquid drug comprising a drug in a base liquid, the liquid drug having a liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between substantially 1300 nm and 2000 nm, the method comprising:

emitting electromagnetic radiation at the liquid drug, the electromagnetic radiation comprising a plurality of different wavelengths between substantially 1300 nm and 2000 nm, wherein at least one of the wavelengths is at or in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum,

detecting affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug and providing output representing spectral information of the liquid drug spectrum at the wavelengths,

querying a database of reference liquid drugs and corresponding spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a reference drug in a base liquid, each reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising the at least one spectral characteristic feature between substantially 1300nm and 2000nm, there being sufficient spectral differences between the reference liquid drug spectrums at the least one spectral characteristic feature of the base liquid spectrum to provide discrimination between reference drugs, and

identifying or verifying the liquid drug using;

a) the output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs, wherein the discrimination between the reference drugs assists with the identifying or verifying the liquid drug.

11. A method according to claim 10 wherein the electromagnetic radiation comprises a plurality of electromagnetic radiation beams, each beam having a different wavelength.

12. A method according to claim 10 wherein the wavelengths span or capture a plurality of at least some of the spectral characteristic features in the liquid spectrum between 1300 nm and 2000 nm.

13. A method according to claim 10 wherein the liquid spectrum comprises two or more spectral characteristic features, and wherein:

each spectral characteristic feature falls in or spans a region of the liquid spectrum, and

each wavelength falls within one of the regions.

14. A method according to claim 10 wherein the spectral characteristic features comprise peaks, troughs, inflections, stable points or regions, plateaus, knees and/or slopes of the liquid spectrum.

15. A method according to claim 10 wherein the electromagnetic radiation is generated using a source comprising a plurality of lasers, each laser configured to emit an electromagnetic radiation beam at a fixed or tuneable wavelength.

16. A method according to claim 10 wherein the detector and/or source are temperature compensated to provide temperature stability, using thermistors and peltier devices in a closed loop system.

17. A method according to claim 10 further comprising:

turning off the source and measuring the output, resulting in a dark current component, and

removing the dark current component from the output representing the detected affected modulated electromagnetic radiation.

18. A method according to claim 10, wherein the output is provided by a detector, the method further comprising emitting electromagnetic radiation at the detector so it is unaffected by the liquid drug, and measuring the output of the detector resulting from the emitted electromagnetic radiation unaffected by the liquid drug.